- Latest available (Revised)
- Point in Time (02/12/2019)
- Original (As made)
Point in time view as at 02/12/2019.
There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) Regulations 2004, SCHEDULE 4.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Regulation 16(6)
1.—(1) Subject to the following sub-paragraphs, where the United Kingdom Ethics Committee Authority (“the Authority”) receive a notice pursuant to regulation 16(3) [F1, (4)(b)] or (7) that a chief investigator wishes to appeal against an ethics committee opinion which is not favourable, the Authority shall, subject to sub-paragraph (2)—U.K.
(a)direct that the application for that opinion may be considered by another ethics committee specified in the direction; or
(b)appoint a panel in accordance with paragraph 3 (“an appeal panel”) and refer the opinion to that panel.
(2) Subject to sub-paragraph (4), the Authority may refuse to give a direction or appoint a panel pursuant to sub-paragraph (1) where it considers that the grounds for appealing against the opinion are unfounded.
(3) Where the Authority refuse to give a direction or appoint a panel pursuant to sub-paragraph (1), the Authority shall send a notice to the chief investigator setting out their reasons for refusal.
(4) Where the opinion was given by the Gene Therapy Advisory Committee, the Authority must appoint a panel in accordance with paragraph 3 and refer the opinion to that panel.
Textual Amendments
F1Word in Sch. 4 para. 1(1) inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 30(a)
2. Where a direction is given in accordance with paragraph 1(1)(a)—U.K.
(a)the ethics committee which gave the unfavourable opinion shall—
(i)send the application for that opinion, and
(ii)any additional information provided by the chief investigator,
to the ethics committee specified in the direction; and
(b)that committee shall consider the application in accordance with regulation 15.
3.—(1) An appeal panel appointed pursuant to paragraph 1(1)(b) shall consist of a chairman and at least 6 other members.U.K.
(2) One of the members shall be a person who is not—
(a)a health care professional,
(b)a person having professional qualifications or experience relating to the conduct of, or use of statistics in, clinical trials, unless those professional qualifications or experience relate only to the ethics of clinical research or medical treatment, or
(c)a person who, although not a health care professional, has been a registered medical practitioner or a person registered in the dentists register under the Dentists Act 1984.
4.—(1) An appeal panel shall consider an ethics committee opinion referred to it in accordance with the following sub-paragraphs.U.K.
(2) The appeal panel shall consider—
(a)the opinion;
(b)the application for that opinion;
(c)the particulars and documents accompanying that application;
(d)the matters specified in regulation 15 [F2(5)];
(e)any representations set out in the notice to the Authority; and
(f)in a case where the opinion has been confirmed by the Gene Therapy Advisory Committee F3... pursuant to regulation 16 [F4(6)], the reasons given by the Committee for that confirmation.
(3) The panel may, if the chief investigator so requests, hold a hearing to consider the opinion, at which the chief investigator may make oral representations.
(4) The panel shall within 30 days of the opinion being referred to the panel, or such extended period as the Authority may in any particular case allow, either confirm the opinion or give a favourable opinion.
Textual Amendments
F2Word in Sch. 4 para. 4(2)(d) substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 30(b)(i)
F3Words in Sch. 4 para. 4(2)(f) omitted (29.8.2006) by virtue of The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 30(b)(ii)(aa)
F4Word in Sch. 4 para. 4(2)(f) substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 30(b)(ii)(bb)
5. If an appeal panel gives a favourable opinion, the condition specified in regulation [F512](3)(a) shall be deemed to have been satisfied.U.K.
Textual Amendments
F5Word in Sch. 4 para. 5 substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 30(c)
6. The Authority may pay to members of an appeal panel such travelling and other allowances as the Authority may determine.U.K.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: